Výsledky vyhledávání - "Bertin Ushizimpumu"

Akademický článek

Rifampicin resistance conferring mutations among Mycobacterium tuberculosis strains in Rwanda

Autor: Isabel Cuella-Martin, Jean Claude Semuto Ngabonziza, Gabriela Torrea, Conor Joseph Meehan, Wim Mulders, Bertin Ushizimpumu, Louise De Weerdt, Jelle Keysers, Willem Bram De Rijk, Tom Decroo, Bouke C De Jong, Leen Rigouts

Publikováno v: International Journal of Mycobacteriology, Vol 12, Iss 3, Pp 274-281 (2023)

Background: The World Health Organization-endorsed phenotypic and genotypic drug-susceptibility testing (gDST/pDST) assays for the detection of rifampicin-resistant (RR) tuberculosis (TB), may miss some clinically relevant rpoB mutants, including bor

Externí odkaz: https://doaj.org/article/7a88442c84f742f5967729b57118eea6

Zobrazit plný text záznamu

Akademický článek

Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century

Publikováno v: Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, Vol 27, Iss , Pp 100299- (2022)

Summary background: Multidrug-resistant (MDR) tuberculosis (TB) poses an important challenge in TB management and control. Rifampicin resistance (RR) is a solid surrogate marker of MDR-TB. We investigated the RR-TB clustering rates, bacterial populat

Externí odkaz: https://doaj.org/article/8c83389e22714bf5b35ec4ced1dcdb5e

Zobrazit plný text záznamu

Akademický článek

Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda

Autor: Jean Claude Semuto Ngabonziza, MSc, Tom Decroo, PhD, Patrick Migambi, MSc, Yves Mucyo Habimana, MD, Armand Van Deun, PhD, Conor J Meehan, PhD, Gabriela Torrea, PhD, Faridath Massou, PharmD, Willem Bram de Rijk, BS, Bertin Ushizimpumu, BS, Esdras Belamo Niyigena, BS, Emil Ivan, PhD, Jules Mugabo Semahore, MD, Jean Baptiste Mazarati, PhD, Corinne Simone Merle, PhD, Philip Supply, PhD, Dissou Affolabi, ProfPhD, Leen Rigouts, PhD, Bouke Catherine de Jong, ProfPhD

Publikováno v: The Lancet Microbe, Vol 1, Iss 2, Pp e74-e83 (2020)

Summary: Background: The Xpert MTB/RIF (Xpert) assay is used globally to rapidly diagnose tuberculosis and resistance to rifampicin. We investigated the frequency and predictors of false-positive findings of rifampicin resistance with Xpert. Methods:

Externí odkaz: https://doaj.org/article/77bfaae837f3401fad6757b6a7eea198

Zobrazit plný text záznamu

Rifampicin-Resistant Tuberculosis Control in Rwanda Overcomes a Successful Clone That Causes Most Disease Over a Quarter Century

Publikováno v: SSRN Electronic Journal.

Background: Rifampicin-resistance (RR) poses an important challenge in tuberculosis (TB) management and control. Understanding the driving factors behind the rising numbers of RR-TB is important for developing appropriate control strategies. Methods:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3357e43218817294f771d472754f55b5
https://doi.org/10.2139/ssrn.3792898

Zobrazit plný text záznamu

Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis

Autor: Armand Van Deun, Bertin Ushizimpumu, Wim Mulders, Patrick Migambi, Leen Rigouts, Philip Supply, Jean Claude Semuto Ngabonziza, Bouke C. de Jong, Théogène Dusabe, Tom Decroo, Esdras Belamo Niyigena, Yves Mucyo Habimana, Dissou Affolabi

Publikováno v: American Journal of Tropical Medicine and Hygiene
American Journal of Tropical Medicine and Hygiene, American Society of Tropical Medicine and Hygiene, 2020, 103 (4), pp.1443-1446. ⟨10.4269/ajtmh.20-0201⟩
American Journal of Tropical Medicine and Hygiene, 2020, 103 (4), pp.1443-1446. ⟨10.4269/ajtmh.20-0201⟩
The American journal of tropical medicine and hygiene
The American Journal of Tropical Medicine and Hygiene

International audience; We report a case of acquired fluoroquinolone (FQ) resistance under short-course multidrug-resistant tuberculosis (MDR-TB) treatment. The patient was managed at Kabutare hospital, one of the two specialized MDR-TB clinics in Rw

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daa8b39d5651dc8cf881587e07b7549f
https://hal.archives-ouvertes.fr/hal-03053951

Zobrazit plný text záznamu

Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda

Autor: Faridath Massou, Patrick Migambi, Armand Van Deun, Dissou Affolabi, Corinne S Merle, Bertin Ushizimpumu, Esdras Belamo Niyigena, Jean Baptiste Mazarati, Leen Rigouts, Bouke C. de Jong, Conor J. Meehan, Emil Ivan, Philip Supply, Jules Mugabo Semahore, Willem Bram de Rijk, Tom Decroo, Gabriela Torrea, Yves Mucyo Habimana, Jean Claude Semuto Ngabonziza

Publikováno v: Lancet microbe
The Lancet Microbe
The Lancet Microbe, Elsevier, 2020, 1 (2), pp.e74-e83. ⟨10.1016/S2666-5247(20)30007-0⟩
The Lancet Microbe, 2020, 1 (2), pp.e74-e83. ⟨10.1016/S2666-5247(20)30007-0⟩
The Lancet Microbe, Vol 1, Iss 2, Pp e74-e83 (2020)

Summary Background The Xpert MTB/RIF (Xpert) assay is used globally to rapidly diagnose tuberculosis and resistance to rifampicin. We investigated the frequency and predictors of false-positive findings of rifampicin resistance with Xpert. Methods We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ac9c3937ab1c223d8876192a9c61ba9
https://pubmed.ncbi.nlm.nih.gov/35544156

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání